Ascletis Pharma Inc. has announced that a petition for Post Grant Review has been filed with the United States Patent and Trademark Office by Conjupro Biotherapeutics, Inc., a subsidiary of CSPC Pharmaceutical Group Limited. The petition challenges the validity of specific claims in one of Ascletis Pharma's granted U.S. patents. The patent in question covers the molecular structure of Compound 1, which is identical to Compound 10 in CSPC's pending patent application. Ascletis had filed its patent application approximately three months before CSPC's application. The petition is currently under review by the USPTO, and its potential impact on Ascletis cannot be determined at this stage. The company will monitor developments closely and inform shareholders and investors of any significant updates.